- Home
- JSPR vs ATNM Comparison
JSPR vs ATNM Comparison
Compare JSPR & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ATNM
- Stock Information
- Founded
- JSPR 2018
- ATNM 2000
- Country
- JSPR United States
- ATNM United States
- Employees
- JSPR N/A
- ATNM N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ATNM Health Care
- Exchange
- JSPR Nasdaq
- ATNM Nasdaq
- Market Cap
- JSPR 47.6M
- ATNM 50.2M
- IPO Year
- JSPR N/A
- ATNM N/A
- Fundamental
- Price
- JSPR $2.45
- ATNM $1.47
- Analyst Decision
- JSPR Buy
- ATNM Strong Buy
- Analyst Count
- JSPR 11
- ATNM 2
- Target Price
- JSPR $28.00
- ATNM $4.50
- AVG Volume (30 Days)
- JSPR 439.0K
- ATNM 163.5K
- Earning Date
- JSPR 11-06-2025
- ATNM 11-13-2025
- Dividend Yield
- JSPR N/A
- ATNM N/A
- EPS Growth
- JSPR N/A
- ATNM N/A
- EPS
- JSPR N/A
- ATNM N/A
- Revenue
- JSPR N/A
- ATNM N/A
- Revenue This Year
- JSPR N/A
- ATNM N/A
- Revenue Next Year
- JSPR N/A
- ATNM N/A
- P/E Ratio
- JSPR N/A
- ATNM N/A
- Revenue Growth
- JSPR N/A
- ATNM N/A
- 52 Week Low
- JSPR $2.22
- ATNM $1.03
- 52 Week High
- JSPR $26.05
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- JSPR 46.88
- ATNM 39.85
- Support Level
- JSPR $2.33
- ATNM $1.47
- Resistance Level
- JSPR $2.65
- ATNM $1.59
- Average True Range (ATR)
- JSPR 0.15
- ATNM 0.07
- MACD
- JSPR 0.03
- ATNM -0.01
- Stochastic Oscillator
- JSPR 53.32
- ATNM 10.53
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.